Bluebird Bio and Celgene Reports Results of bb21217 in P-I (CRB-402) study for 3L+ r/r Multiple Myeloma

 Bluebird Bio and Celgene Reports Results of bb21217 in P-I (CRB-402) study for 3L+ r/r Multiple Myeloma

Celgene and Acceleron Report FDA’s Acceptance of BLA for Luspatercept to Treat Myelodysplastic Syndromes and Beta-Thalassemia

 Shots:

  • The P-I CRB-402 study involves assessing of bb21217 as an investigational anti- BCMA CAR T (150 x 106) cell therapy in patients with r/r multiple myeloma
  • The study demonstrated 83% of total patients (N=12) achieved an objective clinical response; CR 3, VGPR 2; 4 PR; with no death occurred
  • bb21217 is an anti-BCMA CAR T cell therapy targeted to kill plasma & myeloma cells expressing B cell maturation antigen (BCMA) and is jointly developed by Bluebird Bio and Celgene

Click here to read full press release/ article | Ref: Bluebird Bio | Image: Wral Techwire

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post